Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 3/20 | 0.58 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ESRRG | P62508 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4985408 | 0.84 | SLC6A5 (0.57) | NAMPTKCNA5SLC6A5NPC1RAB9A | |
| SCHEMBL2873843 | 0.82 | NAMPT (0.64) | NAMPTNPC1RAB9AESRRG | |
| SCHEMBL12434160 | 0.81 | KCNA5 (0.61) | NAMPTKCNA5SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL4679965 | 0.79 | F10 (0.48) | NAMPTKCNA5KDRNPC1TP53 | |
| SCHEMBL7079568 | 0.78 | NAMPT (0.57) | NAMPTSMN1; SMN2KDM4ELMNAALDH1A1 | |
| SCHEMBL24352345 | 0.78 | KCNA5 (0.57) | NAMPTKCNA5KDM4EALDH1A1CA1 | |
| SCHEMBL29473197 | 0.78 | KCNA5 (0.57) | NAMPTKCNA5KDM4EALDH1A1CA1 | |
| SCHEMBL25762436 | 0.78 | KCNA5 (0.56) | NAMPTKCNA5LMNACA1NQO2 | |
| SCHEMBL12434478 | 0.78 | KCNA5 (0.73) | KCNA5NPC1RAB9A | |
| SCHEMBL13789545 | 0.78 | KCNA5 (0.64) | NAMPTKCNA5SMN1; SMN2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964730-B2 | Amino-substituted ethylamino β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-20090111850-A1 | Amino-Substituted Ethylamino Beta2 Adrenergic Receptor Agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111850-A1 | Amino-Substituted Ethylamino Beta2 Adrenergic Receptor Agonists | ADRB2, ADRB1, ADRA2A | NAMPT 3500/4885KCNA5 604/4885SMN1; SMN2 1912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.